Bio-Rad Laboratories (www.bio-rad.com) inked two transactions with Quest Diagnostics (www.questdiagnostics.com) to place BioPlex® 2200 systems and autoimmune test reagents as well as HIV-1/HIV-2 PLUS O EIA assay. Quest Diagnostics will use the latter to detect HIV-1 and HIV-2 in their network of reference laboratories nationwide. The BioPlex 2200 system is an automated random access testing system employing multiplex technology to simultaneously generate multiple results from a single small patient sample, according to Bio-Rad. In early April, Bio-Rad reported that it had released Epstein Barr Virus kits to run on the BioPlex 2200 system and that it has more than 15 other multiplex reagent kits in development for the system.

Previous articleKing Enters Asset Purchase Agreement with JHP Pharmaceuticals Worth $90M
Next articleEvotec Grows its GMP Sterile Pharmaceutical Production Plant